Pharmacological Comparison of Dostarlimab and Pembrolizumab in Metastatic Non-Small Cell Lung Cancer in PERLA

被引：0
|
作者：
Samant, T. S. [1 ]
Struemper, H. [2 ]
Franzese, R. C. [1 ]
Goulooze, B. [3 ]
Muliaditan, M. [3 ]
Melhem, M. [4 ]
Ghosh, S. [1 ]
Fastenrath, M. [5 ]
Stjepanovic, N. [6 ]
Szijgyarto, Z. [7 ]
Rathi, C. [1 ]
Mantero, A. [1 ]
Hanafin, P. [1 ]
Zajic, S. [1 ]
Yanamandra, N. [1 ]
Chung, C-W.
Vlahovic, G.
机构：
[1] GSK, Collegeville, PA USA
[2] GSK, Durham, NC USA
[3] LAP&P Consultants, Leiden, Netherlands
[4] GSK, Waltham, MA USA
[5] GSK, London, England
[6] GSK, Baar, Switzerland
[7] GSK, Stevenage, Herts, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
基金：
芬兰科学院;
关键词：
mNSCLC; Tumor Size-Overall Survival Modeling; Clinical Pharmacology;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4.11E.28
引用
收藏
页码：S407 / S408
页数：2
相关论文
共 50 条
  • [1] Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
    Lim, Sun Min
    Peters, Solange
    Granados, Ana Laura Ortega
    Pinto, Gustavo dix Junqueira
    Fuentes, Christian Sebastian
    Lo Russo, Giuseppe
    Schenker, Michael
    Ahn, Jin Seok
    Reck, Martin
    Szijgyarto, Zsolt
    Huseinovic, Neda
    Zografos, Eleftherios
    Buss, Elena
    Stjepanovic, Neda
    ODonnell, Sean
    de Marinis, Filippo
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [2] Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
    Sun Min Lim
    Solange Peters
    Ana Laura Ortega Granados
    Gustavo dix Junqueira Pinto
    Christian Sebastián Fuentes
    Giuseppe Lo Russo
    Michael Schenker
    Jin Seok Ahn
    Martin Reck
    Zsolt Szijgyarto
    Neda Huseinovic
    Eleftherios Zografos
    Elena Buss
    Neda Stjepanovic
    Sean O’Donnell
    Filippo de Marinis
    Nature Communications, 14
  • [3] Dostarlimab plus chemotherapy (CT) vs pembrolizumab plus CT in metastatic non-squamous non-small cell lung cancer (NSCLC): Updated Asian subgroup analyses of the PERLA trial
    Lee, D. H.
    Ahn, J. S.
    Lin, S-H.
    Ulanska, M.
    Lopez, G. A.
    Chian, C-F.
    Cho, L.
    Szijgyarto, Z.
    Stjepanovic, N.
    Lim, S. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1662 - S1663
  • [4] Patient-Reported Outcomes (PROs) in Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC): PERLA Trial Comparing First-Line Chemotherapy Plus Dostarlimab or Pembrolizumab
    Reck, Martin
    Granados, Ana Laura Ortega
    de Marinis, Filippo
    Meyers, Oren
    Shen, Qin
    Cho, Lillian
    Boklage, Susan
    Gouldin, Winston
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E26 - E27
  • [5] Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab
    Reck, Martin
    Granados, Ana Laura Ortega
    de Marinis, Filippo
    Meyers, Oren
    Boklage, Susan
    Shen, Qin
    Cho, Lillian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] EFFECTIVENESS AND SAFETY OF PEMBROLIZUMAB IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
    Murteira, R.
    Ramos, C.
    Cardoso Borges, F.
    Ferreira, M. M.
    Miranda, A.
    da Costa, Alves F.
    VALUE IN HEALTH, 2018, 21 : S15 - S15
  • [7] Pembrolizumab for the treatment of non-small cell lung cancer
    Muller, Mirte
    Schouten, Robert D.
    De Gooijer, Cornedine J.
    Baas, Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (05) : 399 - 409
  • [8] Pembrolizumab for the treatment of non-small cell lung cancer
    Lim, Sung Hee
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (03) : 397 - 406
  • [9] Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer
    Morgensztern, Daniel
    Herbst, Roy S.
    CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3713 - 3717
  • [10] Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab
    Reck, Martin
    Granados, Ana Laura Ortega
    de Marinis, Filippo
    Meyers, Oren
    Shen, Qin
    Cho, Lillian
    Stjepanovic, Neda
    Boklage, Susan
    EUROPEAN JOURNAL OF CANCER, 2024, 212
12345